144 related articles for article (PubMed ID: 15700153)
1. Treosulfan and gemcitabine.
Cree IA; Neale MH; Reinhold U; Kurbacher CM
J Cancer Res Clin Oncol; 2005 May; 131(5):329-30; author reply 331. PubMed ID: 15700153
[No Abstract] [Full Text] [Related]
2. A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours.
Keilholz U; Schuster R; Schmittel A; Bechrakis N; Siehl J; Foerster MH; Thiel E
Eur J Cancer; 2004 Sep; 40(14):2047-52. PubMed ID: 15341977
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
Corrie PG; Shaw J; Spanswick VJ; Sehmbi R; Jonson A; Mayer A; Bulusu R; Hartley JA; Cree IA
Br J Cancer; 2005 Jun; 92(11):1997-2003. PubMed ID: 15886706
[TBL] [Abstract][Full Text] [Related]
4. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Pföhler C; Cree IA; Ugurel S; Kuwert C; Haass N; Neuber K; Hengge U; Corrie PG; Zutt M; Tilgen W; Reinhold U
Anticancer Drugs; 2003 Jun; 14(5):337-40. PubMed ID: 12782938
[TBL] [Abstract][Full Text] [Related]
5. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
Schmittel A; Schuster R; Bechrakis NE; Siehl JM; Foerster MH; Thiel E; Keilholz U
Melanoma Res; 2005 Oct; 15(5):447-51. PubMed ID: 16179873
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.
Schmittel A; Schmidt-Hieber M; Martus P; Bechrakis NE; Schuster R; Siehl JM; Foerster MH; Thiel E; Keilholz U
Ann Oncol; 2006 Dec; 17(12):1826-9. PubMed ID: 16971664
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):685-8. PubMed ID: 18084763
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma.
Terheyden P; Bröcker EB; Becker JC
J Cancer Res Clin Oncol; 2004 Jul; 130(7):395-9. PubMed ID: 15160290
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Schmittel A; Scheulen ME; Bechrakis NE; Strumberg D; Baumgart J; Bornfeld N; Foerster MH; Thiel E; Keilholz U
Melanoma Res; 2005 Jun; 15(3):205-7. PubMed ID: 15917703
[TBL] [Abstract][Full Text] [Related]
10. Medical treatment of uveal melanoma.
Queirolo P; Acquati M
Tumori; 2007; 93(3):suppl 27-30. PubMed ID: 17679486
[No Abstract] [Full Text] [Related]
11. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Knight LA; Di Nicolantonio F; Whitehouse P; Mercer S; Sharma S; Glaysher S; Johnson P; Cree IA
BMC Cancer; 2004 Nov; 4():83. PubMed ID: 15560844
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Neale MH; Myatt N; Cree IA; Kurbacher CM; Foss AJ; Hungerford JL; Plowman PN
Br J Cancer; 1999 Mar; 79(9-10):1487-93. PubMed ID: 10188895
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Br J Cancer; 2007 Nov; 97(10):1329-32. PubMed ID: 17971774
[TBL] [Abstract][Full Text] [Related]
14. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo.
Saakyan SV; Tsygankov АY; Moiseeva NI; Karamysheva АF; Garri DD
Bull Exp Biol Med; 2020 Nov; 170(1):142-147. PubMed ID: 33231795
[TBL] [Abstract][Full Text] [Related]
16. Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Am J Clin Oncol; 2011 Feb; 34(1):2-5. PubMed ID: 20042970
[TBL] [Abstract][Full Text] [Related]
17. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Thigpen T
Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
Glaysher S; Gabriel FG; Johnson P; Polak M; Knight LA; Parker K; Poole M; Narayanan A; Cree IA;
Br J Cancer; 2010 Aug; 103(5):656-62. PubMed ID: 20700122
[TBL] [Abstract][Full Text] [Related]
19. Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Nitsch E; Mina S; Brammer I; Pace A; Schuch G; Bokemeyer C; Zander A; Kröger N; Ayuk F
Anticancer Res; 2014 Apr; 34(4):1779-84. PubMed ID: 24692710
[TBL] [Abstract][Full Text] [Related]
20. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Ugurel S; Schadendorf D; Pföhler C; Neuber K; Thoelke A; Ulrich J; Hauschild A; Spieth K; Kaatz M; Rittgen W; Delorme S; Tilgen W; Reinhold U;
Clin Cancer Res; 2006 Sep; 12(18):5454-63. PubMed ID: 17000680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]